(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)
`(19) World Intellectual Property
`Organization
`International Bureau
`
`(43) International Publication Date
`29 June 2017 (29.06.2017)
`
`WIPO!IPCT
`
`\=
`
`(10) International Publication Number
`WO 2017/109488 Al
`
`GD)
`
`International Patent Classification:
`C07D 403/12 (2006.01)
`CO7D 417/14 (2006.01)
`C07D 413/14 (2006.01)
`C07D 207/10 (2006.01)
`C07D 413/12 (2006.01)
`A61IK 31/40 (2006.01)
`C07D 417/12 (2006.01)
`A61P 35/00 (2006.01)
`
`2)
`
`International Application Number:
`
`(22)
`
`International Filing Date:
`
`PCT/GB2016/054022
`
`21 December 2016 (21.12.2016)
`
`(25) Filing Language:
`(26) Publication Language:
`(30) Priority Data:
`1522768.9
`23 December 2015 (23.12.2015)
`
`GB
`
`(71) Applicant: MISSION THERAPEUTICS LIMITED
`[GB/GB]; Moneta (Building 280), Babraham Research
`Campus, Cambridge CB22 3AT (GB).
`
`(72)
`
`Inventors: KEMP, Mark Ian; C/o Mission Therapeutics
`Limited, Moneta (Building 280), Babraham Research Cam-
`pus, Cambridge CB22 3AT (GB). WOODROW, Michael
`David; C/o Mission Therapeutics Limited, Moneta (Build-
`ing 280), Babraham Research Campus, Cambridge CB22
`3AT (GB).
`
`(81) Designated States (unless otherwise indicated, for every
`kind of national protection available): AE, AG, AL, AM,
`AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
`BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM,
`DO, DZ, EC, EE, EG, ES, FL GB, GD, GE, GH, GM,GT,
`HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN,
`KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
`MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
`NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
`RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY,
`TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,
`ZA, ZM, ZW.
`English
`English (g4) Designated States (unless otherwise indicated, for every
`kind of regional protection available): ARIPO (BW, GH,
`GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
`TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
`TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
`DK,EE, ES, FL FR, GB, GR, HR, HU,IE,IS, IT, LT, LU,
`LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
`SM, TR), OAPI (BEF, BJ, CF, CG, CI, CM, GA, GN, GQ,
`GW, KM,ML,MR,NE, SN, TD, TG).
`Published:
`
`with international search report (Art. 21(3))
`
`(74)
`
`Agent: STRATAGEM INTELLECTUAL PROPERTY
`MANAGEMENT LIMITED, Meridian Court, Comber-
`ton Road, Toft, Cambridge CB23 2RY (GB).
`
`(54) Title: CYANOPYRROLIDINE DERVIVATIVES AS INHIBITORS FOR DUBS
`
`
`
`we mg
`
`
`
`“GeRMRRESEOETES 4
`
`“AALAMAAEALAERPPLEEAEP
`
`
`
`a
`
`(1)
`
`
`
`2017/109488AiIMIIIMIITNATAIIATTATAHOAMERICAA
`
`(57) Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating
`enzymes (DUBs). In particular, the inventionrelates to the inhibition of Cezanne 1 and ubiquitin C-terminal hydrolase 30 or Ubi-
`quitin Specific Peptidase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of cancer. Com -
`poundsof the invention include compounds having the formula (I): pharmaceutically acceptable salt thereof, wherein R'*, R', R',
`= RR Rand A are as defined herein.
`
`

`

`WO 2017/109488
`
`PCT/GB2016/054022
`
`CYANOPYRROLIDINE DERVIVATIVES AS INHBITORS FOR DUBS
`
`The present invention relates to novel compounds and methods for the manufacture of inhibitors of
`
`deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of Cezanne 1.
`
`The invention further relates to the use of DUB inhibitors in the treatment of cancer.
`
`
`Background to the Invention
`
`The listing or discussion of an apparently prior-published document in this specification should not
`
`necessarily be taken as an acknowledgement that the document is part of the state of the art or is
`
`10
`
`commongeneral knowledge.
`
`Ubiquitin is a small protein consisting of 76 amino acids that is important for the regulation of protein
`
`function in the cell. Ubiquitylation and deubiquitylation are enzymatically mediated processes by
`
`which ubiquitin is covalently bound or cleaved from a target protein. These processes have been
`
`implicated in the regulation of many cellular functions including cell cycle progression, apoptosis,
`
`modification of cell surface receptors, regulation of DNA transcription and DNA repair. Thus, the
`
`ubiquitin system has been implicated in the pathogenesis of numerous disease states including
`
`inflammation, viral infection, metabolic dysfunction, CNS disorders, and oncogenesis.
`
`Ubiquitin molecules are cleaved from proteins by deubiquitylating enzymes (DUBs), of which there
`
`are approximately 95 DUBs in humancells, divided into sub- families based on sequence homology.
`
`The ovarian tumour (OTU) family consists of at least 14 active DUBs and are characterised by the
`
`presence of an OTU domainand the tendencyto cleave ubiquitin chains in a linkage specific manner.
`
`Cezanne |, also known as OTUD7B, is an 843 amino acid protein that was identified owing to its
`
`similarity to the OTU family member A20 that has been shown biochemically to have a strong
`
`preference for K11 ubiquitin chain linkages.
`
`Cezanne | has been shownto act as a negative regulator of both the canonical and the non-canonical
`
`NF-«B pathway. It has been shown that Cezanne | acts on the canonical pathway by processing K63
`
`chains on the RIP1 protein and on the non-canonical pathway by deubiquitylation of the inhibitory
`
`component TRAF3 (TNFreceptor associated factor 3).
`
`It has also been shown to have a role in
`
`hypoxia by regulating HIFla (hypoxia inducible factor la) protein levels. Cezanne 1 siRNA
`
`decreased HIFla protein levels under hypoxia, and accordingly decreased HIFloa target gene
`
`expression. Knockdown of Cezanne |
`
`led to higher levels of apoptosis following hypoxia. Since
`
`HIFla has oncogenic properties, and Cezanne | has a pro-survival role in hypoxia, Cezanne | has
`
`been suggested to be a goodtarget for pharmacological intervention.
`
`15
`
`20
`
`25
`
`30
`
`35
`
`

`

`WO 2017/109488
`
`PCT/GB2016/054022
`
`Cezanne | has been shownto have a role in cell proliferation, migration and invasion by antagonizing
`
`EGFR(epidermal growth factor receptor) internalisation and degradation. Cezanne 1 and Cezanne 2
`
`were identified in a genetic screen to find a DUB enzyme for EGFR. Cezanne | overexpressionled to
`
`higher levels of phosphorylated EGFR, lower levels of ubiquitylated EGFR and EGFRstabilization.
`
`In MDA-MB-231 breast cancer cells, knockdown of Cezanne 1
`
`led to decreased invasion and
`
`migration. Analysis of The Cancer Genome Atlas by Pareja et al., showed that Cezanne 1 was
`
`overexpressed in breast cancer and amplification of the gene was seen in a third of breast tumours.
`
`The level of Cezanne | expression correlated with poor prognosis.
`
`10
`
`Although there has been a handful of DUB inhibitors published in the literature, there is a continuing
`
`need for compounds and pharmaceutical compositions which inhibit DUBs such as Cezanne | and
`
`USP30 for the treatment of cancer and other indications where DUBactivity is observed.
`
`15
`
`Summary of the Invention
`
`In accordance with a first aspect of the invention there is provided a compound of formula (1)
`
`a
`
`oewe
`
`GRAAL
`
`LALALES
`
`(1)
`
`20
`
`or a pharmaceutically acceptable salt thereof, wherein:
`R'* RR" and R' each independently represent hydrogen or an optionally substituted C-C, alkyl,
`or R'is linked to R™ to form an optionally substituted cycloalkyl ring, or R'’ is linked to R'® or R" to
`
`form an optionally substituted cycloalkyl ring;
`R"° and R" each independently represent hydrogen, fluorine, cyano, hydroxyl, amino, optionally
`
`25
`
`substituted C,-C, alkyl, optionally substituted C,-C, alkoxy or an optionally substituted 5 or 6
`memberedaryl or heteroaryl ring, or R'® and R"together form an optionally substituted cycloalkyl
`ring, or R" is linked to R' to form an optionally substituted cycloalkyl ring;
`
`A is an optionally substituted 5 to 10 membered heteroaryl or aryl ring.
`
`30
`
`

`

`WO 2017/109488
`
`PCT/GB2016/054022
`
`A may represent a 5 to 10 membered heteroaryl or aryl ring substituted with onc or more of Q'-(R”)n.
`
`wherein:
`
`nis Oor 1;
`-
`-NR*COR*,
`-CONR’R*,
`-NR°R*,
`-SR’,
`-OR®,
`Q'
`represents halogen, cyano, oxo, nitro,
`NR*CONR'R’, -COR’, -C(O)OR*, -SO2R*, -SO:NR°R", -NR*SO,R*, -NR*SO.NR'R’, -NR°C(O)OR’,
`
`optionally substituted -C,-C, alkyl, optionally substituted -C,-C, alkoxy, optionally substituted —C2-C,
`
`alkenyl, optionally substituted —C2-C. alkynyl, a covalent bond, an oxygen atom, a sulphur atom, -SO-
`, “SO.-,
`-CO-,
`-C(O)O-,
`-CONR’*-,
`-NR*-,
`-NR*CO-,
`-NR*CONR"-,
`-SO2NR*-,
`-NR*SO,-,
`-
`NR’SO,NR*-,
`-NR°C(O)O-,
`-NR*C(O)OR*-, optionally substituted C)-C, alkylene or optionally
`
`10
`
`substituted -C2-C, alkenylene;
`R°, R‘ and R° each independently represent hydrogen, optionally substituted C\-C, alkyl or optionally
`
`substituted C,-C, alkylene.
`
`Whennis 1, R’ represents an optionally substituted 3 to 10 membered heterocyclyl, heteroaryl, aryl
`15
`or cycloalkyl ring. (When n is 0, Q; is present and R’is absent).
`
`R’ maybeoptionally substituted with onc or more substituents sclected from halogen, cyano, oxo,
`nitro, -OR®, -SR°, -NR°R’, -CONR®R’, -NR°COR’, -NR°CONR’R*, -COR®,-C(O)OR*®, -SO,R’,-
`SO;NR°R’, -NR°SO>R’, NR°SO,NR’R®, -NR°C(O)OR’, optionally substituted -C)-C, alkyl,
`
`optionally substituted -C)-C, alkoxy, optionally substituted —C.-C, alkenyl, optionally substituted -C2-
`Cs alkynyl, -Q’-R°, -Q’-NR°CONR’R®, -Q’-NR°R’, -Q?-COR®, -Q’-NR°COR’, -Q’-NR°C(O)OR’,-
`Q’-SO2R°, Q’-CONR‘’R’, -Q’-CO2R°, -Q’-SO,NR°R’, —Q’-NR°SO>R’ and -Q’-NR°SO,NR’R*;
`
`wherein
`
`Q’ represents a covalent bond, an oxygen atom, a sulphur atom, -SO-, -SO,-, -CO-, optionally
`
`substituted C,-C, alkylene or optionally substituted C2-C, alkenylene; and
`R°, R’, R® each independently represent hydrogen, optionally substituted C\-C, alkyl, optionally
`
`substituted heterocyclyl, optionally substituted heteroaryl, optionally substituted aryl, or an optionally
`
`substituted cycloalkyl.
`
`In one aspect, the invention also relates to pharmaceutical compositions comprising the compounds of
`
`the present invention and one or more pharmaceutically acceptable excipients.
`
`In another aspect, the compoundsof the invention are useful for the treatment of cancer.
`
`20
`
`25
`
`30
`
`35
`
`

`

`WO 2017/109488
`
`PCT/GB2016/054022
`
`
`Bnicf Description of the Figures
`
`Figure | provides an image of Cezanne 1 purified from mammalian cells. FLAG-purified protein or
`
`the indicated concentrations of BSA were separated by SDS-PAGEandstained with Impenal (Pierce
`
`Biotechnology).
`
`Figure 2 is a graph showing proteolytic activity of Cezanne 1 measured using a fluorescence
`
`polarisation assay. Various volumes of purified Cezanne | as indicated were incubated with a
`
`TAMRA labelled peptide linked to ubiquitin via an isopeptide bond.
`
`10
`
`
`Detailed Description of the Invention
`
`The definitions and explanations below are for the terms as used throughout this entire document
`
`including both the specification and the claims. Reference to compounds as described herein (e.g. a
`
`compound of formula (I),
`
`includes reference to formula (1) and (IT)
`
`including any sub-generic
`
`embodiments thereof, e.g. formula (JA).
`
`15
`
`20
`
`25
`
`30
`
`35
`
`Where any group of the compounds of formula (I) have been referred to as optionally substituted, this
`
`group may be substitutcd or unsubstituted. Substitution may be by onc or morc of the spccificd
`
`substituents which may be the same ordifferent.
`
`It will be appreciated that the numberand nature of
`
`substituents will be selected to avoid any sterically undesirable combinations.
`
`In the context of the present specification, unless otherwise stated an alkyl, alkylene, alkoxy, alkenyl,
`
`or alkynyl substituent (or linker) group or an alkyl, alkenyl moiety in a substituent group may be
`
`linear or branched. Alkyl, alkylene, alkenyl and alkenylene chains may also include intervening
`
`heteroatoms such as oxygen.
`
`C,-C,alkyl refers to a saturated aliphatic hydrocarbon group having x-y carbon atoms which may be
`
`linear or branched. For example C,-C, alkyl contains from | to 6 carbon atoms and includes C,, Co,
`
`Cs, Ca, Cs and Cs. “Branched” meansthat at least one carbon branch point is present in the group.
`
`For example, tert-butyl and isopropyl are both branched groups. Examples of C,-C, alkyl groups
`
`include methyl, ethyl, propyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl, 3-methyl-1-
`
`butyl, 2-methyl-3-butyl, 2,2-dimethyl-l-propyl, 2-methyl-pentyl, 3-methyl-l-pentyl, 4-methyl-1-
`
`pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl-
`
`1-butyl, 2-ethyl-1-butyl, n-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl and n-hexyl. C,-
`Cz alkyl, C\-C, alkyl and Cj-C; alkyl within the definitions of R', R'’, R', R'?, R'®, RY, R’, RY R?,
`R°, R’, R®, Q', and within the definition of substituents for R’, may be unsubstituted or substituted
`
`

`

`WO 2017/109488
`
`PCT/GB2016/054022
`
`with onc or morc of the substituents defined herein. Examples of substituted Ci-Ce alkyl thercforc
`
`include CF3, CH,CFs, CH,CN, CH,OH and CH,CH,OH.
`
`A C,-C, alkylene group or moiety may be linear or branched and refers to a divalent hydrocarbon
`
`group having one less hydrogen atom from C,-C, alkyl as defined above. C)-C, alkylene may include
`
`intervening heteroatoms such as oxygen, and therefore includes alkyleneoxy groups. Alkyleneoxy as
`
`employed herein also extends to embodiments in which the or an oxygen atom (e.g. a single oxygen
`
`atom) is located within the alkylene chain, for example CH,CH,OCH, or CH,OCH;. Examples of Cy.
`
`C.s alkylene groups include methylene, methyleneoxy, ethylene, ethyleneoxy, n-propylene, n-
`
`propyleneoxy, n-butylene, n-butyleneoxy, methylmethylene and dimethylmethylene. Unless stated
`otherwise, C,-C, alkylene, C,-C, alkylene and C,-C; alkylene within the definitions of R?, RR’, Q'
`and Q’ may be unsubstituted or substituted with one or more of the substituents defined herein.
`
`C.-C, alkenyl refers to a linear or branched hydrocarbon chain radical containing at least two carbon
`
`atoms and at least one double bond and includes C,-C, alkenyl. Examples of alkenyl groups include
`
`ethenyl, propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 1-hexenyl, 2-methyl-1-propenyl, 1,2-butadienyl,
`
`1,3-pentadicnyl, 1,4-pentadicnyl and 1-hcexadicnyl. Unless stated otherwise, C2-C¢ alkenyl and C2-C,
`alkenyl within the definitions of Q' and within the definition of substituents for R’, may be
`
`unsubstituted or substituted with one or more of the substituents defined herein.
`
`10
`
`15
`
`20
`
`C.-C, alkenylene refers to linear or branched hydrocarbon group having one less hydrogen atom
`
`from C2-C, alkenyl as defined above. Examples of C:-C, alkenylene include ethenylene, propenylene
`
`and butenylene. Unless stated otherwise, C:-C, alkenylene and C.-C, alkenylene within the definition
`of substituents for Q' and Q’, may be unsubstituted or substituted with one or more of the substituents
`
`25
`
`defined herein.
`
`C.-C, alkynyl refers to a linear or branched hydrocarbon chain radical containing at least two carbon
`
`atoms and at least one triple bond. Examples of alkenyl groups include ethynyl, propynyl, 2-
`
`propynyl, 1-butynyl, 2-butynyl and l-hexynyl. Unless specified otherwise, C3-C, alkynyl, within the
`definitions of Q' and within the definition of substituents for R’, may be unsubstituted or substituted
`
`30
`
`with one or more of the substituents defined herein.
`
`C,-Cg alkoxy refers to a group or part of a group having an -O-C,.C, alkyl group according to the
`
`definition of C,.C, alkyl above. C,-C, alkoxy contains from 1 to 6 carbon atoms and includes C), C2,
`
`35
`
`Cs, C4, Cs and Cs. Examples of C)-C, alkoxy include methoxy, ethoxy, propoxy, isopropoxy, butoxy,
`
`pentoxy and hexoxy. Alkoxy as employed herein also extends to embodiments in which the or an
`
`

`

`WO 2017/109488
`
`PCT/GB2016/054022
`
`oxygen atom (c.g. a single oxygen atom) 1s located within the alkyl chain, for example CH2CH2,OCH3
`
`or CH,0CH;. Thus the alkoxy may be linked through carbon to the remainder of the molecule, for
`
`example, -CH,CH,OCHs, or alternatively, the alkoxy is linked through oxygento the remainder ofthe
`
`molecule, for example -OC, alkyl.
`
`In certain instances, the alkoxy may be linked through oxygen to
`
`the remainder of the molecule but the alkoxy group contains a further oxygen atom, for example —
`
`OCH:;CH.20OCH:;. Unless specified otherwise, C)-C, alkoxy and C,-C; alkoxy within the definitions
`R'*, RQ! and within the definition of substituents for R’, may be unsubstituted or substituted with
`
`one or more of the substituents defined herein. Examples of substituted C,-C, alkoxy therefore
`
`include OCF3, OCHF,, OCH2CF;, CH2CH2,OCH; and CH,CH,0CH2CHs.
`
`The term “halogen” or “halo” refers to chlorine, bromine, fluorine or iodine atoms,
`
`in particular
`
`chlorine or fluorine atoms.
`
`The term “oxo” means =O.
`
`For the avoidance of doubtit will be understood that the cycloalkyl, heterocyclyl, aryl and heteroaryl
`rings disclosed herein and within the definitions of R'*, R', R', R'! R'®, R'!, R?, R°, R’, R®ring A,
`and within the definition of substituents for R’, do not include any unstable ring structures or, in the
`
`case of heteroaryl and heterocyclic rings systems, any O-O, O-S or S-S bonds. The ring systems may
`
`be monocyclic or bicyclic. Bicyclic ring systems include bridged, fused and spiro ring systems. A
`
`substituent if present may be attached to any suitable ring atom which may be a carbon atom or,in the
`
`case of heteroaryl and heterocyclic ring systems, a heteroatom. Substitution on a ring may also
`
`include a change in the ring atom at the position of the substitution. For example, substitution on a
`
`phenyl ring may include a change in the nng atom at the position of substitution from carbon to
`
`10
`
`15
`
`20
`
`25
`
`nitrogen, resulting in a pyridine ring.
`
`“cycloalkyl” refers to a monocyclic saturated or partially unsaturated, non-aromatic ring, wherein all
`
`of the ring atoms are carbon, and having the numberof ring atoms as indicated. For example C3-Cjo
`
`cycloalkyl refers to a monocyclic or bicyclic hydrocarbon ring containing 3 to 10 carbon atoms.
`
`Examples of C3-Ciy cycloalkyl are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl,
`
`cyclooctyl and decahydronaphthalenyl. Bicyclic cycloalkyl groups include bridged ring systems such
`
`as bicycloheptane and bicyclooctane. Unless specified otherwise, cycloalkyl within the definitions of
`R™ R’, RI RI RI RY R?, RR’, R® and within the definition of substituents for R’, may be
`unsubstituted or substituted with one or more of the substituents defined herein.
`
`30
`
`35
`
`

`

`WO 2017/109488
`
`PCT/GB2016/054022
`
`An “aryl” group / moicty refers to any monocyclic or bicyclic hydrocarbon group compnisingat Icast
`
`one aromatic group and having from 5 to 10 carbon atom ring members. Examples of aryl groups
`
`include phenyl and naphthyl. Bicyclic mnngs may be fused aromatic mngs where both mngs are
`
`aromatic, for example, naphthalenyl. Preferred aryl groups are phenyl and naphthyl, more preferably
`phenyl. Unless specified otherwise, aryl within the definitions of RR" R?, R° R’, RR’, ring, A, and
`within the definition of substituents for R’, may be unsubstituted or substituted with one or more of
`
`the substituents defined herein.
`
`10
`
`15
`
`20
`
`25
`
`30
`
`“Heteroaryl” as used herein means a polyunsaturated, monocyclic or bicyclic 5 to 10 membered
`
`aromatic moiety containing at least one and up to 5 heteroatoms, particularly 1, 2 or 3 heteroatoms
`
`selected from N, O and S, and the remaining ring atoms are carbon atoms, in stable combinations
`
`knownto the skilled person. Heteroaryl ring nitrogen and sulphur atomsare optionally oxidised, and
`
`the nitrogen atom(s) are optionally quaternized. A heteroaryl ring can be a single aromatic ring or a
`
`fused bicyclic ring where the bicyclic mng system can be aromatic, or one of the fused rings is
`
`aromatic and the otheris at least partially saturated.
`
`In one example, a bicyclic heteroaryl is one in
`
`which the entire fused ring system is aromatic. Examples of fused rings where one of the rings is
`
`aromatic
`
`and the othcr
`
`is
`
`at
`
`lcast partially saturated include
`
` tctrahydropyridopyrazinyl,
`
`tetrahydroquinolinyl and tetrahydroisoquinolinyl. In such instances, attachmentof the bicyclic ring to
`
`the group it is a substituent of relative to the cyanopyrrolidine core, e.g. attachment of mng A via the
`
`amide group, is from the aromatic ring of the bicycle. A bicyclic heteroaryl can have the at least one
`
`heteroatom in either of the fused rings. For example, a bicyclic ring with an aromatic ring fused to a
`
`partially saturated ring may contain the at least one heteroatom in the aromatic ring or the partially
`
`saturated ring. Attachment of the bicyclic ring to the group it is a substituent of may be via either a
`
`heteroatom containing ring or a carbon only containing ring. The point of attachment of heteroaryl to
`
`the group it is a substituent of can be via a carbon atom or a heteroatom (e.g. nitrogen). Examples of
`
`heteroaryl
`
`rings include pyridinyl, pyrazinyl, pynmidinyl, pyridazinyl, furyl, pyrrolyl, oxazolyl,
`
`thiazolyl, pyrazolyl,
`
`tnazolyl,
`
`tetrazolyl,
`
`indolyl,
`
`indolizinyl,
`
`isoindolyl, purinyl,
`
`furazanyl,
`
`imidazolyl,
`
`indazolyl,
`
`isothiazolyl,
`
`isoxazolyl, oxadiazolyl,
`
`tetrazolyl,
`
`thiadiazolyl, benzofuranyl,
`
`isobenzofuranyl,
`
`benzothiophenyl,
`
`1sobenzothiophenyl,
`
`benzimidazolyl,
`
`benzothiazolyl,
`
`napthyndinyl, ptendinyl, pyrazinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl,
`
`imidazopynidinyl,
`
`pyrazolopyridinyl,
`
`thiazolopyridinyl,
`
`tnazinyl,
`
`dihydrophyridiny1,
`
`dihydropyrrolopyridinyl,
`
`indolinyl,
`
`isoindolinyl,
`
`quinoxalinyl,
`
`benzomorpholinyl,
`
`
`tetrahydropyndopyrazinyl, tetrahydroquinolinyl and_tetrahydroisoquinolinyl. Unless specified
`
`
`otherwise, heteroaryl within the definitions of R', RR? R®,R’, R® ring, A, and within the definition
`of substituents for R’, may be unsubstituted or substituted with one or more ofthe substituents defined
`
`35
`
`herein.
`
`

`

`WO 2017/109488
`
`PCT/GB2016/054022
`
`“Heterocyclyl’ or “heterocyclic” as used herein in describing a ring means, unless otherwise stated, a
`
`monocyclic saturated or partially unsaturated, non-aromatic ring or a bicyclic saturated or partially
`
`unsaturated ring, wherein the bicyclic ring system 1s non-aromatic, the mono- or bicyclic ring having,
`
`for example, 3 to 10 members, where at least one member and up to 5 members, particularly 1, 2 or 3
`
`members of the rng are heteroatoms selected from N, O and S, and the remaining ring atoms are
`carbon atoms, in stable combinations knownto those ofskill in the art. For example, R’ and R° may
`
`together form a heterocyclic ring which incorporates the amine nitrogen. Heterocyclic rng nitrogen
`
`and sulphur atoms are optionally oxidised, and the nitrogen atoms(s) are optionally quaternized. As
`
`used herein, the heterocyclic ring may be a fused ring to another ring system to form a bicycle, 1.c.
`
`one or two of the heterocyclic ring carbons is common to an additional ring system.
`
`In instances
`
`wherethe heterocylcyl is a bicyclic ring, the second ring can be aromatic, e.g. a fused phenyl, pyridyl,
`
`pyrazolyl, or the like. The bicyclic heterocyclyl can have at least one heteroatom in either of the
`
`fused nngs. The heterocyclyl may be linked through carbon or a heteroatom to the remainder of the
`
`molecule and in instances where the heterocylyl is a bicyclic ring, the link may be via the heteroatom
`
`containing ring or the fused ring.
`
`In instances where the heterocyclyl is a bicyclic ring where the
`
`second ring is aromatic, attachment of the bicyclic group to the group it is a substituent of relative to
`
`the cyanopyrrolidine core is from the non-aromatic ring. Examples of heterocyclyl groups include
`
`azetidinyl, pyrrolidinyl, piperidinyl, azepanyl, diazepanyl, dihydrofuranyl (e.g. 2,3-dihydrofuranyl,
`
`2,5-dihydrofuranyl), dioxolanyl, morpholinyl, oxazolidinyl, oxazinanyl,
`
`indolinyl,
`
`isoindolinyl,
`
`piperazinyl,
`
`tetrahydrofuranyl,
`
`thiomorpholinyl, dihydropyranyl
`
`(e.g. 3,4-dihydropyranyl, 3,6-
`
`dihydropyranyl), homopiperazinyl, dioxanyl, hexahydropynmidinyl, pyrazolinyl, pyrazolidinyl, 4H-
`
`10
`
`15
`
`20
`
`
`
`quinolizinyl, tetrahydropyndinyl,—tetrahydropyrimidinyl,quinuclidinyl, tetrahydropyranyl,
`
`
`
`
`
`25
`
`30
`
`35
`
`tetrahydrothiophenyl,
`thiazolidinyl, benzopyranyl,
`tetrahydroquinolinyl, benzomorpholinyl
`and
`tetrahydroisoquinolinyl. Unless specified otherwise, heterocyclyl within the definitions of R’, R°, R’,
`R® and within the definition of substituents for R’, may be unsubstituted or substituted with one or
`
`more of the substituents defined herein. Examples of substituted heterocyclyl mngs include for
`
`example 4,5-dihydro-1H-maleimido,tetramethylenesulfoxide and hydantoinyl.
`
`“Optionally substituted” as applied to any group means that the said group may if desired be
`
`substituted with one or more substituents (e.g., 1, 2, 3 or 4 substituents) which may be the same or
`
`different.
`
`Examplesof suitable substituents for “substituted” and “optionally substituted” C,-C, alkyl (including
`
`C.-C, alkyl, Ci-C; alkyl and C.-C, alkyl) and C,-C, alkoxy Gncluding C)-C, alkoxy, C)-C; alkoxy and
`
`C.-C, alkoxy) and C.-C, alkenyl
`
`(Gncluding C.-C, alkenyl) and C2-C, alkynyl Gincluding C.-C,
`
`

`

`WO 2017/109488
`
`PCT/GB2016/054022
`
`alkynyl), for cxample within the definitions of R', R', R', R'? R'*, R™ R®, R*, R°, R° RR’, R® Q',
`and within the definition of substituents for R’, and C.-C, alkylene (including C,-C; alkylene) and C,-
`C. alkenylene, for example within the definitions of R*, R*, R°, Q' and Q’, include halogen, hydroxyl,
`
`thiol, cyano, amino, nitro and SF; (a known mimetic of nitro), in particular, halogen (preferably
`
`fluorine or chlorine), hydroxyl and cyano.
`
`Examples of suitable substituents for “substituted” and “optionally substituted” rings, 1.c. cycloalkyl,
`heterocyclyl, aryl and heteroaryl rings, for example within the definitions of R'*, R', R', R'?, RY,
`R", R’, R°, R’, R*, ring A, and within the definition of substituents for R’, include halogen, cyano,
`
`oxo, nitro, amino, hydroxy, C,-C¢, alkyl or C-C3 alkyl, Ci-C¢ alkoxy or C)-C3 alkoxy, aryl, heteroaryl,
`
`heterocyclyl, C3-Cs cycloalkyl, C,; alkylamino, C2 alkenylamino, di-C,-C3; alkylamino, C,-C;
`
`acylamino, di-C,-C; acylamino, carboxy, C)-C; alkoxycarbonyl, carboxamidyl, carbamoyl, mono-C,.;
`
`carbamoyl, di-C).3 carbamoyl! or any of the above in which a hydrocarbyl moiety is itself substituted
`
`by halogen, e.g. fluorine, hydroxyl, cyano, amino, nitro or SFs (a known mimetic of nitro).
`
`In groups
`
`containing an oxygen atom such as hydroxy and alkoxy, the oxygen atom can be replaced with
`
`sulphur to make groups such as thio (SH) and thio-alkyl (S-alkyl). Optional substituents therefore
`
`include groups such as S-mcthyl.
`
`In thio-alkyl groups, the sulphur atom may bc further oxidised to
`
`make a sulfoxide or sulfone, and thus optional substituents therefore includes groups such as S(O)-
`
`alkyl and S(O)s-alkyl.
`
`Examples of suitable substituents for “substituted” and “optionally substituted” rings include in
`
`particular,
`
`fluorine, chlorine, oxo, cyano, C)-C; alkyl, Ci-C; alkoxy, heterocyclyl, cycloalkyl,
`
`heteroary or aryl, wherein the alkyl or alkoxy is optionally substituted with one or more(e.g. one, two
`
`or three) substituents selected from halogen, hydroxyl, thiol, cyano, amino, nitro and SF3.
`
`Substituted groups thus include for example Br, Cl, F, CN, Me, Et, Pr, Bu, 1-Bu, OMe, OEt, OPr,
`
`C(CHs3)3, CH(CHs3)2, CF3, OCF:, C(O)NHCHs;, cyclopropyl, phenyl, etc.
`
`In the case of aryl groups,
`
`the substitutions may be in the form of rings from adjacent carbon atomsin the aryl ring, for example
`
`cyclic acetals such as O-CH;-O.
`
`The term "treat" or "treating" or “treatment” includes prophylaxis and means to ameliorate,
`
`alleviate symptoms, eliminate the causation of the symptoms either on a temporary or permanent
`
`basis, or to prevent or slow the appearance of symptoms of the named disorder or condition. The
`
`compoundsof the invention are useful in the treatment of humans and non-humananimals.
`
`10
`
`15
`
`20
`
`25
`
`30
`
`35
`
`

`

`WO 2017/109488
`
`PCT/GB2016/054022
`
`The dose of the compound is that amount cffective to prevent occurrence of thc symptoms of the
`
`disorder or to treat some symptoms of the disorder from which the patient suffers. By "effective
`
`amount" or "therapeutically effective amount" or "effective dose" is meant that amount sufficient
`
`to elicit the desired pharmacological or therapeutic effects, thus resulting in effective prevention or
`
`treatment of the disorder. Prevention of the disorder is manifested by delaying the onset of the
`
`symptoms of the disorder to a medically significant extent. Treatment of the disorder is manifested by
`
`a decrease in the symptomsassociated with the disorder or an amelioration of the reoccurrence of the
`
`symptoms of the disorder.
`
`Pharmaceutically acceptable salts of the compounds of the invention include but are not limited to
`
`addition salts (for example phosphates, nitrates, sulphates, borates, acetates, maleates, citrates,
`
`fumarates, succinates, methanesulphonates, benzoates, salicylates and hydrohalides), salts derived
`
`from organic bases (such as lithium, potasstum and sodium), salts of amino acids (such as glycine,
`
`alanine, valine,
`
`leucine,
`
`isoleucine, cysteine, methionine and proline),
`
`inorganic bases (such as
`
`triethylamine,
`
`hydroxide,
`
`choline,
`
`thiamine
`
`and N-N’-diacetylethylenediamine).
`
`Other
`
`pharmaceutically acceptable salts
`
`include ammonium salts,
`
`substituted ammonium salts and
`
`aluminium salts. Further pharmaccutically acccptable salts include quaternary ammoniumsalts of the
`
`compoundsof the invention.
`
`General methods for the production of salts are well known to the person skilled in the art. Such salts
`
`may be formed by conventional means, for example by reaction of a free acid or a free base form of a
`
`compound with one or more equivalents of an appropriate acid or base, optionally in a solvent, or in a
`
`medium in whichthe salt is insoluble, followed by removal of said solvent, or said medium, using
`
`standard techniques (e.g. in vacuo, by freeze-drying or by filtration). Salts may also be prepared by
`
`exchanging a counter-ion of a compound in the form of a salt with another counter-ion, for example
`
`using a suitable ion exchangeresin.
`
`Where compoundsof the invention exist in different enantiomeric and/or diastereoisomeric forms, the
`
`invention relates to these compounds prepared as isomeric mixtures or racemates whether present in
`
`an optically pure form or as mixtures with other isomers. Enantiomers differ only in their ability to
`
`rotate plane-polarized light by equal amounts in opposite directions and are denotedas the (+) / (S) or
`
`(-) / (R) forms respectively. Individual enantiomers or isomers may be prepared by methods known in
`
`the art, such as optical resolution of products or intermediates (for example chiral chromatographic
`
`separation e.g. chiral HPLC, or an asymmetric synthesis approach). Similarly where compounds of
`
`the invention exist as alternative tautomeric forms e.g. keto/enol, amide/imidic acid, the invention
`
`relates to the individual tautomers in isolation, and to mixtures of the tautomers 1n all proportions.
`
`10
`
`15
`
`20
`
`25
`
`30
`
`35
`
`10
`
`

`

`WO 2017/109488
`
`PCT/GB2016/054022
`
`Included herein is the compound according to formula (ID
`
`v
`i
`,
`&
`SSA.
`Ae
`
`ce
`:
`‘
`3
`|a.
`oll,
`7 we —wea .
`iN
`
` ¥ ~ Ne,
`
`we
`
`ca
`
`(II)
`
`or a pharmaceutically acceptable salt thereof, wherein:
`R' R', R'° and R'* each independently represent hydrogen or an optionally substituted C,-C, alkyl,
`or R'is linked to R" to forman optionally substituted cycloalkyl ring, or R'is linked to R'* or R™to
`
`form an optionally substituted cycloalkyl ring;
`R" and R"each independently represent hydrogen, fluorine, cyano, hydroxyl, amino, optionally
`
`10
`
`substituted C,-C, alkyl, optionally substituted C)-C, alkoxy or an optionally substituted 5 or 6
`memberedring, or R'° and R"together form an optionally substituted cycloalkyl ring, or R'° is linked
`to R' to form an optionally substituted cycloalkylring;
`
`A is an optionally substituted 5 to 10 membered heteroaryl or aryl ring.
`
`15
`
`20
`
`25
`
`30
`
`Isotopes
`
`The compounds described herein may contain one or more isotopic substitutions, and a reference to a
`
`particular element includes within its scopeall isotopes of the element. For example, a reference to
`hydrogen includes within its scope 'H, 7H (D), and *H (T). Similarly, references to carbon and
`oxygen include within their scope respectively '"C, °C and "C and '°O and '*O. Examples of
`isotopes include *H, *H, 'C, °C, “C, *°Cl, °F, I, '7I, °N, °N, °O, ’O, O, *°P and *S.
`
`In an analogous manner, a reference to a particular function

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.

We are unable to display this document.

PTO Denying Access

Refresh this Document
Go to the Docket